The Metis Foundation
15
3
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
20%
3 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Role: collaborator
SN514-066b Enzyme in Deep Partial Thickness Burns
Role: collaborator
Assessment Of Burn Severity and Extent Spatial Frequency Domain Imaging
Role: lead
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
Role: lead
A Prospective Study Using SupraSDRM® in Promoting Healing and Reducing the Time to Grafting of Full-thickness Wounds
Role: lead
Antibiotic Concentrations After MassivE Transfusion Study
Role: collaborator
Manual Implantation of Full-Thickness Skin Microcolumns
Role: lead
A Case-Control Study of Negative Pressure Platform Wound Devices (NP-PWD) for Skin and Soft Tissue Defects
Role: lead
The Use of a Platform Wound Device for Reducing Infection
Role: lead
Microscopic Skin Tissue Column Grafting Technique Using the Autologous Regeneration of Tissue System
Role: lead
Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers
Role: lead
Addressing Anxiety and Stress for Healthier Eating in Teens
Role: lead
Effects of Pulsed Dye and CO2 Laser in Treatment of Hypertrophic Burn Scars.
Role: lead
A Case Series Study of Negative Pressure Platform Wound Device
Role: lead
Procellera® Compared to Standard of Care Treatment in Mitigating Biofilm Formation in Acute Trauma and Burn Wounds
Role: lead
All 15 trials loaded